Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

This study is testing a drug called trilaciclib, given alongside standard chemotherapy, as a pre-surgery (neoadjuvant) treatment for osteosarcoma (a type of bone cancer). Trilaciclib is designed to protect bone marrow during chemotherapy, potentially reducing side effects and improving outcomes. **You may be eligible if...** - You have been newly diagnosed with high-grade osteosarcoma (confirmed by biopsy), stage II or III - You are planning to have neoadjuvant (pre-surgery) chemotherapy - You have not had any previous cancer treatments - You are in good general health (ECOG performance status 0–1) - You have adequate organ function - You agree to use effective contraception during and for 6 months after treatment **You may NOT be eligible if...** - You have a history of another type of cancer - You are allergic to the study drug - You have a history of substance abuse or alcohol use disorder - The investigator determines you are not suitable for the study Talk to your doctor to see if this trial is right for you.